| All patients, N = 137 | High IFN5, N = 96 | Low IFN5, N = 41 |
---|---|---|---|
Age; mean ± SD (range) | 36.4 ± 14.1 (18–76.3) | 33.6 ± 12.5 (18–66.6) | 43.0 ± 15.6 (18–76.3) |
Female Sex; N (%) | 118 (86.1) | 83 (86.5) | 35 (85.4) |
Disease duration (years); mean ± SD (range) | 10.8 ± 9.2 (0–48.5) | 9.7 ± 8.3 (0–33.3) | 13.3 ± 10.6 (0.1–48.5) |
SLEDAI-2K; mean ± SD (range) | 6.6 ± 6.3 (0–29) | 7.4 ± 6.8 (0–29) | 4.8 ± 4.8 (0–20) |
cSLEDAI-2K; mean ± SD (range) | 4.7 ± 5.6 (0–25) | 5.3 ± 6.0 (0–25) | 3.3 ± 4.2 (0–16) |
Clinical features; N (%) | |||
 CNS | 3 (2.2) | 2 (2.1) | 1 (2.4) |
 Vasculitis | 4 (2.9) | 3 (3.1) | 1 (2.4) |
 Arthritis | 17 (13.1) | 15 (15.6) | 2 (4.9) |
 Myositis | 0 (0) | 0 (0) | 0 (0) |
 Nephritis | 52 (38.0) | 35 (36.4) | 17 (41.5) |
 Rash | 21 (15.3) | 18 (18.8) | 3 (7.3) |
 Alopecia | 22 (16.8) | 18 (18.8) | 4 (9.8) |
 Ulcers | 13 (9.5) | 12 (12.5) | 1 (2.4) |
 Pleuritis | 4 (2.9) | 3 (3.1) | 1 (2.4) |
 Pericarditis | 2 (1.5) | 1 (1.0) | 1 (2.4) |
 Low complement | 59 (43.1) | 42 (43.8) | 17 (41.5) |
 dsDNA Abs | 75 (54.7) | 61 (63.5) | 14 (34.1) |
 Fever | 5 (3.6) | 4 (4.2) | 1 (2.4) |
 Thrombocytopenia | 4 (2.9) | 3 (3.1) | 1 (2.4) |
 Leukopenia | 3 (2.2) | 3 (3.1) | 0 (0) |
SDI; mean ± SD (range) | 1.4 ± 1.6 (0–8) | 1.2 ± 1.6 (0–8) | 1.8 ± 1.6 (0–5) |
Prednisone dose (mg); mean ± SD (range) | 15.9 ± 20.7 (0–150) | 16.8 ± 21.9 (0–150) | 13.7 ± 17.5 (0–60) |
Anti-malarials; N (%) | 104 (75.9) | 73 (76.0) | 31 (75.6) |
Immunosuppressives; N (%) | 86 (62.8) | 63 (65.6) | 23 (56.1) |
 Azathioprine | 35 (25.5) | 25 (26.0) | 10 (24.4) |
 Mycophenolate | 45 (32.8) | 33 (34.4) | 12 (29.3) |
 Methotrexate | 7 (5.1) | 6 (6.2) | 1 (2.4) |
 Cyclosporine | 2 (1.5) | 1 (1.0) | 1 (2.4) |
 Cyclophosphamide | 2 (1.5) | 2 (2.1) | 0 (0) |
 Others | 1 (0.7) | 1 (1.0) | 0 (0) |